AstraZeneca
AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer
June 22, 2018Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma
In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …
Another failure in Alzheimer’s creates bleak outlook for treatment
June 12, 2018Manufacturing and Production, Research and Development Alzheimer's, AstraZeneca, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …
EU gives nod to expanded label for AZ’s Tagrisso
June 11, 2018Sales and Marketing AstraZeneca, Tagrisso, biotech, drugs, pharma, pharmaceutical
AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
Top Ten most popular articles on Pharmafile.com this week
June 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …
AZ’s hopes for Fasenra in COPD suffer terminal blow
May 30, 2018Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …
AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer
May 25, 2018Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …
FDA approves AZ’s Lokelma for hyperkalaemia
May 21, 2018Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma
The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …
Top Ten most popular articles on Pharmafile.com this week
May 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical
It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …
AZ’s Fasenra stumbles in P3 for COPD
May 11, 2018Medical Communications, Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
AstraZeneca jettisons schizophrenia drug for $538 million
May 8, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia
AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …
AZ’s combo woes continue, with failure in lung cancer
April 24, 2018Manufacturing and Production, Research and Development AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …
AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
April 19, 2018Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma
AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …
Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso
April 13, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma
South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
